cloNIDine
Drug Name | Form | Strength | Formulary Unrestricted | Formulary Restricted | Non-Formulary | Interchange |
---|---|---|---|---|---|---|
Catapres-TTS-1 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.1 mg/24 hr | ||||
Catapres-TTS-2 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.2 mg/24 hr | ||||
Catapres-TTS-3 | FILM, EXTENDED RELEASE, TRANSDERMAL | 0.3 mg/24 hr | ||||
Duraclon | SOLUTION, INJECTABLE | 1000 mcg/10 mL | ||||
Nexiclon XR | SUSPENSION, EXTENDED RELEASE, ORAL | 0.09 mg/mL | ||||
cloNIDine | SUSPENSION, ORAL | 20 mcg/mL | ||||
Kapvay | TABLET, EXTENDED RELEASE, ORAL | 0.1 mg, 0.2 mg | ||||
Nexiclon XR | TABLET, EXTENDED RELEASE, ORAL | 0.17 mg/24 hr, 0.34 mg/24 hr, 0.52 mg/24 hr | ||||
Catapres | TABLET, ORAL | 0.1 mg, 0.2 mg, 0.3 mg |
NEXICLON XR Suspension is classified as non-formulary, not stocked. Convert to an immediate release clonidine regimen in an equivalent dose.
KAPVAY is restricted to use in pediatric patients.
In adults, interchange to generic immediate release clonidine at same daily dose given bid - qid i.e. Kapvay 0.1 mg bid to clonidine IR 0.1 mg bid, Kapvay 0.2 mg bid to clonidine IR 0.1 mg qid. Inpatients may use home supply
Reviewed: March 22, 2011, and May 24, 2011 (NEXICLON XR), and 15 December 2015 (Kapvay), and 25 April 2017 (Duraclon)
Updated: January 2020 (KAPVAY)